Sense Biodetection and Biotecom have entered an agreement for the non-exclusive distribution of the former’s Veros Covid-19 molecular testing platform in Chile.

The instrument-free Veros Covid-19 platform uses rapid molecular amplification technology and aims to improve access to quick, highly accurate, point-of-care testing.

It is claimed to be the first and only self-contained, single-use Covid-19 product that provides PCR-quality results in 15 minutes without the need for any external power supply or reader.

Veros helps to reduce the spread of Covid-19 through quick and precise diagnoses.

In a multicentre study, Veros Covid-19 was found to be easy to use, with all test site operators reporting that the device was easy to read and the results easy to understand, with less hands-on time.

Veros Covid-19 can detect all variants of interest and concern, including Omicron and its identified subvariants, currently identified by the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sense Biodetection chief commercial officer Ryan Roberts said: “This agreement is significant for Sense as it marks our entry into the South American markets.

“Together with Biotecom, we believe that by adding the instrument-free Veros Covid-19 to their portfolio, healthcare providers in Chile will be able to provide faster diagnosis and exceptional care for their patients right at the point of use by taking advantage of this rapid, laboratory-quality molecular test.”

Founded in 2013, Biotecom distributes quality molecular biotechnology products and reagents to national hospitals, clinics and laboratories in Chile.

In March, Sense Biodetection’s Veros Covid-19 molecular diagnostic test obtained CE Mark.